Ken Griffin Athira Pharma, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 14,300 shares of ATHA stock, worth $4,004. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,300

Previous 17,200 16.86%

Holding current value

$4,004

Previous $10,000 60.0%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.28 - $0.59 $13,880 - $29,248	49,573 New	49,573 $13,000
Q2 2024 Aug 14, 2024	SELL	$1.92 - $2.71 $105,148 - $148,413	-54,765 Reduced 50.65%	53,349 $141,000
Q1 2024 May 15, 2024	SELL	$2.24 - $4.15 $4,421 - $8,192	-1,974 Reduced 1.79%	108,114 $296,000
Q4 2023 Feb 14, 2024	SELL	$1.39 - $2.46 $4,735 - $8,381	-3,407 Reduced 3.0%	110,088 $267,000
Q3 2023 Nov 14, 2023	SELL	$1.9 - $3.16 $192,832 - $320,711	-101,491 Reduced 47.21%	113,495 $229,000
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.59 $682,917 - $1.04 Million	-289,372 Reduced 57.37%	214,986 $634,000
Q1 2023 May 15, 2023	SELL	$2.26 - $4.22 $179,694 - $335,536	-79,511 Reduced 13.62%	504,358 $1.26 Million
Q4 2022 Feb 14, 2023	BUY	$2.76 - $3.71 $394,922 - $530,856	143,088 Added 32.46%	583,869 $1.85 Million
Q3 2022 Nov 14, 2022	SELL	$2.93 - $3.96 $1.2 Million - $1.62 Million	-408,206 Reduced 48.08%	440,781 $1.31 Million
Q2 2022 Aug 15, 2022	BUY	$2.74 - $13.43 $405,794 - $1.99 Million	148,100 Added 21.13%	848,987 $2.59 Million
Q1 2022 May 16, 2022	SELL	$8.96 - $13.51 $556,864 - $839,646	-62,150 Reduced 8.15%	700,887 $9.46 Million
Q4 2021 Feb 14, 2022	SELL	$9.17 - $16.39 $3.42 Million - $6.11 Million	-372,512 Reduced 32.8%	763,037 $9.94 Million
Q3 2021 Nov 15, 2021	SELL	$9.15 - $11.09 $559,586 - $678,231	-61,157 Reduced 5.11%	1,135,549 $10.7 Million
Q2 2021 Aug 16, 2021	SELL	$10.24 - $20.87 $679,567 - $1.39 Million	-66,364 Reduced 5.25%	1,196,706 $12.3 Million
Q1 2021 May 17, 2021	BUY	$16.9 - $29.77 $1.72 Million - $3.03 Million	101,912 Added 8.78%	1,263,070 $23.2 Million
Q4 2020 Feb 16, 2021	BUY	$16.48 - $34.3 $1.37 Million - $2.85 Million	83,143 Added 7.71%	1,161,158 $39.8 Million
Q3 2020 Nov 16, 2020	BUY	$16.02 - $18.46 $17.3 Million - $19.9 Million	1,078,015 New	1,078,015 $19.9 Million

Others Institutions Holding ATHA

# of Institutions

Shares Held

18.4M

Call Options Held

14.3K

Put Options Held

4.4K

View Full List

About Athira Pharma, Inc.

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $10.6M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

More about ATHA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account